

VPA10987/108/001

Wormaway 230/20 mg Flavoured Film-Coated Tablets for Cats

Variation	Summary	Date
Vet - A2	VNRA - Vet - A2 - Change in the (invented) name of the veterinary medicinal product - A2 Administrative changes: Change in the (invented) name of the veterinary medicinal product	25/06/24
Vet - B43	VNRA - Vet - B43 - Editorial changes to part 2 of the dossier if inclusion in an upcoming procedure concerning part 2 is not possible - B43 Changes to the quality part of the dossier: Editorial changes to part 2 of the dossier if inclusion in an upcoming procedure concerning part 2 is not possible	06/03/24
Vet - G.I.18	VRA-S - Vet - G.I.18 - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004 - G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	16/10/23
Vet - C10 a)	VNRA - Vet - C10 a) - a) Administrative information concerning the holder's representative - C10 a) Changes to the safety, efficacy and pharmacovigilance part of the dossier: Changes to the labelling or the package leaflet which shall not be connected with the SPC: — administrative information concerning the holder's representative	27/02/23
Vet - B44	VNRA - Vet - B44 - Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile active substance, starting material, reagent or intermediate, excipient - B44 Changes to the quality part of the dossier: Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile: — active substance; — starting material, reagent or intermediate used in the manufacturing process of the active substance; — excipient	16/01/23
Vet - B4 a)	VNRA - Vet - B4 a) - a) Change in the manufacturer of the active substance (including relevant quality control testing sites) - B4 a) Changes to the quality part of the dossier: Changes to the production process or the storage of active substance where no Ph. Eur. CEP is part of the approved dossier of an active substance (including starting material, reagent or intermediate) - change in the manufacturer of the active substance (including relevant quality control testing sites)	08/12/22

Vet - C3	VNRA - Vet - C3 - Change(s) in the SPC, labelling or package leaflet of a generic or hybrid medicinal product following assessment of the same change(s) for the reference product - C3 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the SPC, labelling or package leaflet of a generic or hybrid medicinal product following assessment of the same change(s) for the reference product	24/11/22
Vet - C1	VNRA - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) - C1 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV)	16/09/22
B.I.z	II - B.I.z - z Other variation - B.I.z - QUALITY CHANGES - ACTIVE SUBSTANCE - Other variation	07/04/22
A.2.b	IB - A.2.b - b) for Nationally Authorised Products - A.2.b - ADMINISTRATIVE CHANGES - Change in the (invented) name of the medicinal product - for Nationally Authorised Products	11/03/22